XML 20 R8.htm IDEA: XBRL DOCUMENT v3.24.0.1
Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Operating activities    
Net loss $ (41,441) $ (38,704)
Adjustments to reconcile net loss to net cash used in operating activities:    
Loss on disposal of assets 0 1
Depreciation 398 236
Stock-based compensation expense 4,509 4,256
(Accretion) amortization of (discounts) and premiums on short-term investments, net (921) 632
Release of clinical trial funding commitment 0 139
Changes in operating assets and liabilities:    
Other assets 108 (1,148)
Accounts receivable and unbilled receivable 483 (236)
Prepaid expenses and other current assets 3,169 (443)
Operating lease right-of-use assets 543 545
Accounts payable and accrued expenses 2,831 1,348
Operating lease liabilities (566) (404)
Other liabilities 0 (42)
Net cash used in operating activities (30,887) (33,820)
Investing activities    
Capital expenditures (582) (1,006)
Insurance proceeds from casualty loss 0 114
Maturities of short-term investments 86,552 76,445
Purchases of short-term investments (70,084) (91,233)
Sales of short-term investments 20,309 53,829
Net cash provided by investing activities 36,195 38,149
Financing activities    
Proceeds from exercise of options 0 75
Net cash provided by financing activities 0 75
Net change in cash and cash equivalents 5,308 4,404
Cash and cash equivalents—Beginning of period 16,347 11,943
Cash and cash equivalents—End of period 21,655 16,347
Supplementary disclosure of cash flow activity:    
Cash paid for taxes 1 2
Acquisition of property and equipment included in accounts payable and accrued liabilities 16 232
Supplemental disclosure of non-cash investing and financing activities:    
Cumulative preferred stock dividend adjustment $ 0 $ (414)